Introduction
Lobar atelectasis occurs in 411% of patients with cystic fibrosis (CF) (1, 2) . A large proportion of these do not resolve despite intensive medical treatment. A 31-year-old patient with CF developed a right upper lobe atelectasis which was resistant to conventional medical treatment. Two months later he was started on recombinant human DNase I (rhDNase) which was associated with partial resolution of the atelectasis and reduction in sputum viscoelasticity. Thick sputum plugs were aspirated by a very experienced bronchoscopist, no endobronchial lesion was seen but the chest radiograph following the procedure remained unchanged. Failure of medical treatment prompted a second bronchoscopy.
Fewer secretions were seen on this occasion but the right upper lobe failed to re-expand.
Two months later the patient was treated with rhDNase 2.5 mg nebulized twice daily as part of a clinical trial. Chest radiograph prior to commencing rhDNase still showed the right upper lobe collapse [Plate l(a)]. His FVC was 3.06 1 and FEV, 1.13 1. He did not receive intravenous antibiotics or intensive physiotherapy 15 days prior to commencement on rhDNase.
After about 2 weeks of treatment the patient started producing copious amounts of sputum (approximately 15&200 ml daily). He developed chest pain on the anterior aspect of the right side of his chest and was more breathless. Spirometry on day 14 of treatment with rhDNase was FVC 3.28 1 and FEV, 1.12 1. Sputum production started to decrease and on day 28 a repeat chest radiograph showed partial re-expansion of the right upper lobe [Plate l(b)l.
Fresh sputum samples were obtained on presentation, pre-treatment with rhDNase and on day 28 of treatment with rhDNase and stored at -20°C. The dynamic storage modulus (G'), which reflects the elasticity of the sample, and the dynamic loss modulus (G"), which is related to viscosity of the sputum samples was measured using oscillatory analysis on a parallel plate rheometer (CSL 100, Carri-Med UK) (3, 4) . Viscoelasticity was similar for the samples obtained at presentation and after conventional treatment but significantly reduced after treatment with rhDNase (Fig. 1) . Intermittent positive pressure breathing and nebulized hypertonic saline has been used to facilitate sputum expectoration (5). Bronchoscopy has been utilized for both diagnostic and therapeutic purposes. Unfortunately in this patient the above treatments had little effect.
The high sputum viscosity found in patients with CF has been attributed to the presence of deoxyribonucleic acid (DNA).
The DNA is derived almost entirely from disintegrated neutrophils (6, 7, 8) . RhDNase has been shown to reduce the viscosity of CF sputum in vitro by depolymerizing DNA (9). In our patient treatment with rhDNase resulted in a remarkable reduction of sputum viscosity. Following sufficient treatment the persistent endobronchial obstruction due to thick tenacious secretions was relieved. This 
